NF1 and glioblastoma: Although RAS alterations are not commonly reported in GBMs [21, 23, 45, 46], GBM possesses mutations in genes that contribute to activated KRAS signaling, like neurofibromin-1 (NF1), are observed, which make KRAS signaling a potential target in GBM [3, 5].